Search Within

Shanu Modi

  1. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (37)
  2. Journal Article (27)
Groups
  1. Breast Medicine Service (64)
  2. Department of Medicine (64)
  3. Population Sciences Research Program (64)
  4. Solid Tumor Oncology Division (64)
  5. Survivorship Research (62)
  6. Epidemiology and Biostatistics (50)

More Groups

People
  1. Clifford Hudis (35)
  2. Chau Dang (34)
  3. Larry Norton (34)
  4. Diana Lake (26)
  5. Sujata Patil (25)
  6. Tiffany Traina (24)

More People

Years
  1. 2024 (6)
  2. 2023 (4)
  3. 2022 (5)
  4. 2021 (3)
  5. 2020 (5)
  6. 2019 (7)

More Years

Publications
  1. Journal of Clinical Oncology (22)
  2. Cancer Research (11)
  3. Clinical Breast Cancer (4)
  4. Annals of Oncology (3)
  5. Breast Cancer Research and Treatment (3)
  6. npj Breast Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (22)
  2. American Association for Cancer Research (14)
  3. Elsevier Inc. (6)
  4. Oxford University Press (6)
  5. American Medical Association (3)
  6. Nature Publishing Group (3)

More Publishers

Results (64)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Eng, J.; Yeh, R.; Girshman, J.; Das, J.; Gelblum, D.; Xu, A. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple negative breast cancer: A feasibility study
    Meeting Abstract

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: A feasibility study
    Journal Article

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Breast Cancer Research and Treatment (2022)

    Fulltext@MSK | Save
  • Refractive shifts and changes in corneal curvature associated with antibody-drug conjugates
    Journal Article

    Canestraro, J.; Hultcrantz, M.; Modi, S.; Hamlin, P. A.; Shoushtari, A. N.; Konner, J. A.; Tew, W. P.; Iyengar, N. M.; Heinemann, M.; Abramson, D. H.; more...
    Cornea (2022)

    Fulltext@MSK | Save
  • Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Journal Article

    Ferraro, E.; Singh, J.; Patil, S.; Razavi, P.; Modi, S.; Chandarlapaty, S.; Barrio, A. V.; Malani, R.; Mellinghoff, I. K.; Boire, A.; more...
    npj Breast Cancer (2022)

    Fulltext@MSK | Save
  • Change in HER2 status after neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in patients with HER2-positive early-stage breast cancer
    Meeting Abstract

    Ferraro, E.; Razavi, P.; Chandarlapaty, S.; Modi, S.; Wen, H. Y.; Brogi, E.; Norton, L.; Robson, M. E.; Dang, C. T.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Consolidative use of radiotherapy to block (CURB) oligoprogression: Interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Shepherd, A. F.; Eng, J.; Gelblum, D.; Xu, A. J.; Namakydoust, A.; Iqbal, A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2021)

    Fulltext@MSK | Save
  • Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A phase I study
    Journal Article

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S. W.; Slovin, S. F.; Adamow, M.; Blinder, V. S.; Brahmachary, M.; Carlsen, M.; Comen, E.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients
    Meeting Abstract

    Barrios, D. M.; Wang, D. G.; Blinder, V. S.; Bromberg, J.; Drullinsky, P.; Funt, S. A.; Jhaveri, K. L.; Lake, D.; Lyons, T.; Modi, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save